Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Pasithea Reports Positive Phase 1 Results For PAS-004 in Advanced Cancer
Details : PAS-004 is a next-generation macrocyclic MEK inhibitor. Currently, it is being evaluated in the early-stage clinical trial studies for the NF1-mutated advanced solid tumors.
Brand Name : PAS-004
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2024
Pasithea Completes Enrollment for PAS-004 in Phase 1 Trial
Details : PAS-004 is a next-generation macrocyclic MEK inhibitor. Currently, it is being evaluated in the early-stage clinical trial studies for the NF1-mutated advanced solid tumors.
Brand Name : PAS-004
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 13, 2024
Pasithea Report First Cohort Completion of Initial Dosing in Phase 1 for RAS Mutations
Details : PAS-004 is is a small molecule allosteric inhibitor of MEK 1/2. It is being evaluated for the treatment of neurofibromatosis type 1 and other cancer indications.
Brand Name : PAS-004
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 24, 2024
Pasithea Therapeutics Opens Enrollment in the U.S. for Phase 1 Trial of PAS-004
Details : PAS-004 is is a small molecule allosteric inhibitor of MEK 1/2. It is being evaluated for the treatment of neurofibromatosis type 1 and other cancer indications.
Brand Name : PAS-004
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 13, 2024
Lead Product(s) : CIP-137401
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pasithea Announces FDA Acceptance Of IND for PAS-004 in Advanced Cancer Patients
Details : PAS-004 (CIP-137401) is a macrocyclic MEK 1/2 inhibitor evaluated for patients with MAPK-driven advanced solid tumors with documented RAS, RAF, or NF1 mutations.
Brand Name : PAS-004
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 02, 2024
Lead Product(s) : CIP-137401
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CIP-137401
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PAS-004 is a small molecule allosteric inhibitor of MEK 1/2, which are dual-specificity protein kinases, in the MAPK signaling pathway. It showed positive In vivo preclinical efficacy in NRAS mutation cancer xenograft models.
Brand Name : PAS-004
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2023
Lead Product(s) : CIP-137401
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PAS-004
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
Details : PAS-004 is a first macrocyclic MEK 1/2 Inhibitor small molecule drug which is being investigated for the treatent of RAS, RAF or NF1 mutated solid tumors.
Brand Name : PAS-004
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 29, 2023
Lead Product(s) : PAS-004
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PAS-003
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PAS-003 is a fully humanized proprietary monoclonal antibody targeting α5β1 integrin for the treatment of both sporadic and familial amyotrophic lateral sclerosis (ALS) and other neurological diseases.
Brand Name : PAS-003
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 09, 2023
Lead Product(s) : PAS-003
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PAS-002
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PAS-002 is a proprietary engineered DNA plasmid vaccine to tolerize the immune system to GlialCAM which is found in brain’s white matter. GlialCAM shares a component of its structure that mimics an identical component of EBNA-1, playing a critical role...
Brand Name : PAS-002
Molecule Type : Vaccine
Upfront Cash : Not Applicable
February 23, 2023
Lead Product(s) : PAS-002
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CIP-137401
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : WuXi AppTec
Deal Size : Undisclosed
Deal Type : Agreement
Details : PAS-004 (CIP-137401) is a small molecule allosteric inhibitor of MEK 1/2 in the Ras-Raf-MEK-ERK signaling pathway, which plays critical roles in the regulation of diverse cellular activities, including cell proliferation, survival, differentiation, and m...
Brand Name : PAS-004
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 18, 2023
Lead Product(s) : CIP-137401
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : WuXi AppTec
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?